Rock Springs Capital Management’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-204,878
| Closed | -$45.3M | – | 101 |
|
|
2025
Q4 | $45.3M | Sell |
204,878
-44,524
| -18% | -$7.2M | 2.32% | 12 |
|
|
2025
Q3 | $23.9M | Buy |
249,402
+115,269
| +86% | +$7.36M | 1.4% | 28 |
|
|
2025
Q2 | $6.53M | Buy |
+134,133
| New | +$3.22M | 0.41% | 58 |
|
|
2018
Q4 | – | Sell |
-15,000
| Closed | -$1.32M | – | 136 |
|
|
2018
Q3 | $1.32M | Hold |
15,000
| – | – | 0.05% | 137 |
|
|
2018
Q2 | $1.56M | Hold |
15,000
| – | – | 0.06% | 136 |
|
|
2018
Q1 | $1.2M | Hold |
15,000
| – | – | 0.05% | 142 |
|
|
2017
Q4 | $2.04M | Hold |
15,000
| – | – | 0.09% | 132 |
|
|
2017
Q3 | $2.43M | Hold |
15,000
| – | – | 0.11% | 126 |
|
|
2017
Q2 | $2.25M | Hold |
15,000
| – | – | 0.11% | 127 |
|
|
2017
Q1 | $2.34M | Hold |
15,000
| – | – | 0.14% | 118 |
|
|
2016
Q4 | $3.12M | Buy |
15,000
+2,500
| +20% | +$520K | 0.21% | 97 |
|
|
2016
Q3 | $2.86M | Hold |
12,500
| – | – | 0.18% | 110 |
|
|
2016
Q2 | $2.58M | Hold |
12,500
| – | – | 0.19% | 107 |
|
|
2016
Q1 | $3.17M | Hold |
12,500
| – | – | 0.27% | 98 |
|
|
2015
Q4 | $4.29M | Sell |
12,500
-1,250
| -9% | -$375K | 0.33% | 94 |
|
|
2015
Q3 | $3.5M | Buy |
13,750
+1,250
| +10% | +$357K | 0.28% | 100 |
|
|
2015
Q2 | $3.5M | Buy |
+12,500
| New | +$3.84M | 0.26% | 103 |
|
Rock Springs Capital Management's CDTX Position: Q1 2026 in Review
Rock Springs Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 204,878 shares — an estimated $45.3M sold.
Rock Springs Capital Management first reported a position in CDTX in Q2 2015 and held it in 17 quarters. The position peaked at $45.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Rock Springs Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Rock Springs Capital Management sold 204,878 Cidara Therapeutics shares in Q1 2026, an estimated $45.3M.
- Rock Springs Capital Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 17 quarters.
- Rock Springs Capital Management's Cidara Therapeutics position peaked at $45.3M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.